Published | Report Code | Available Format | Pages |
---|---|---|---|
January 2016 | LS10563 | 87 |
Chapter 1. Research Scope & Methodology
1.1 Market Definition
1.2 Objective
1.3 Market Scope
1.3.1 Market breakdown by type
1.3.2 Market breakdown by drugs
1.3.3 Market breakdown by geography
1.4 Research Methodology and Sources
Chapter 2. Executive Summary
2.1 Key Findings
2.2 Research Summary
Chapter 3. Market Outlook
3.1 Introduction
3.1.1 Applications of muscle relaxants
3.1.1.1 Applications of muscle relaxants in musculoskeletal problems
3.1.1.2 Uses of muscle relaxants in anesthesia
3.1.1.3 Applications of muscle relaxants in facial aesthetics
3.2 Trends in the Muscle Relaxant Market
3.2.1 Growing online retailing of muscle relaxant drugs
3.2.2 Increasing popularity of muscle relaxant treatments in the cosmetic industry
3.3 Factors Driving Growth of the Market and its Impact on Market Forecast
3.3.1 Growing geriatric population
3.3.2 Increasing prevalence of skin diseases and harmful effects of ultra-violet radiation
3.3.3 Increasing usage of neuromuscular blocking agents in surgeries
3.3.4 Increase in disposable income leading to increase in spends on facial aesthetic therapies
3.3.5 Impact analysis of drivers on market forecast
3.4 Factors Hindering Growth of the Market and its Impact on Market Forecast
3.4.1 High capital expenditure
3.4.2 Stringent regulatory requirements
3.4.3 Risks associated with muscle relaxants
3.4.4 Impact analysis of restraints on market forecast
Chapter 4. Global Muscle Relaxant Drugs Market Size and Forecast (2011 – 2020)
4.1 Global Muscle Relaxant Drugs Market, by Type
4.2 Global Muscle Relaxant Drugs Market, by Geography
Chapter 5. Global Muscle Relaxant Drugs Market, by Type
5.1 Facial Aesthetic Relaxants Market
5.1.1 Facial aesthetic muscle relaxants market, by region
5.1.2 Facial aesthetic muscle relaxants market, by drug
5.2 Skeletal Muscle Relaxants Market
5.2.1 Skeletal muscle relaxants market, by geography
5.2.2 Skeletal muscle relaxants market, by drug
5.3 Neuromuscular Blocking Agents Market
5.3.1 Neuromuscular blocking agents market, by geography
5.3.2 Neuromuscular blocking agents market, by type
Chapter 6. Global Muscle Relaxant Drugs Market, by Geography
6.1 North America Muscle Relaxant Drugs Market
6.1.1 North America muscle relaxant drugs market, by type
6.1.2 North America muscle relaxant drugs market, by country
6.2 Europe Muscle Relaxant Drugs Market
6.2.1 Europe muscle relaxant drugs market, by type
6.2.2 Europe muscle relaxant drugs market, by country
6.3 Asia Muscle Relaxant Drugs Market
6.3.1 Asia muscle relaxant drugs market, by type
6.3.2 Asia muscle relaxant drugs market, by country
6.4 Rest of the World Muscle Relaxant Drugs Market
6.4.1 RoW muscle relaxant drugs market, by type
Chapter 7. Drug Approval Process in the U.S. and EU
7.1 Drug approval process in the U.S.
7.2 Drug approval process in the EU
Chapter 8. Competitive Positioning and Market Share Analysis
8.1 Porter's Five Forces of Competitive Position Analysis
8.1.1 Bargaining power of buyers
8.1.2 Bargaining power of suppliers
8.1.3 Threat of new entrants
8.1.4 Intensity of rivalry
8.1.5 Threat of substitutes
8.2 Global Muscle Relaxant Drugs Market Share Analysis
Chapter 9. Company Profiles and Strategic Developments
9.1 Key Company Profiles
9.1.1 F. Hoffmann-La Roche Ltd
9.1.1.1 Business overview
9.1.1.2 Product and service offerings
9.1.2 Johnson & Johnson
9.1.2.1 Business overview
9.1.2.2 Product and service offerings
9.1.3 GlaxoSmithKline plc
9.1.3.1 Business overview
9.1.3.2 Product offerings
9.1.4 Intas Pharmaceuticals Ltd.
9.1.4.1 Business overview
9.1.4.2 Product offerings
9.1.5 Pfizer Inc.
9.1.5.1 Business overview
9.1.5.2 Product offerings
9.1.6 Galderma S.A.
9.1.6.1 Business overview
9.1.6.2 Product offerings
9.1.7 Merck & Co., Inc.
9.1.7.1 Business overview
9.1.7.2 Product offerings
9.2 Strategic Developments in the Muscle Relaxant Drugs Market
Chapter 10. Appendix
10.1 List of Abbreviations
LIST OF TABLES
TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION
TABLE 2 GLOBAL MUSCLE RELAXANT DRUGS MARKET SNAPSHOT
TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 5 GLOBAL MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 6 GLOBAL MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)
TABLE 7 GLOBAL MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2011-2014)
TABLE 8 GLOBAL MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)
TABLE 9 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2011-2014)
TABLE 10 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)
TABLE 11 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET BREAKDOWN BY DRUG, $M (2011-2014)
TABLE 12 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET BREAKDOWN BY DRUG, $M (2015 – 2020)
TABLE 13 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2011-2014)
TABLE 14 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)
TABLE 15 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET BREAKDOWN BY DRUG, $M (2011-2014)
TABLE 16 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET BREAKDOWN BY DRUG, $M (2015 – 2020)
TABLE 17 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2011-2014)
TABLE 18 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 – 2020)
TABLE 19 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 20 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET BREAKDOWN BY TYPE, $M (2015 – 2020)
TABLE 21 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 22 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2015–2020)
TABLE 23 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2011-2014)
TABLE 24 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015–2020)
TABLE 25 EUROPE MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 26 EUROPE MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2015–2020)
TABLE 27 EUROPE MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2011-2014)
TABLE 28 EUROPE MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015–2020)
TABLE 29 ASIA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 30 ASIA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2015–2020)
TABLE 31 ASIA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2011-2014)
TABLE 32 ASIA MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015–2020)
TABLE 33 ROW MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2011-2014)
TABLE 34 ROW MUSCLE RELAXANT DRUGS MARKET BREAKDOWN BY TYPE, $M (2015–2020)
TABLE 35 F. HOFFMANN-LA ROCHE LTD – KEY FACTS
TABLE 36 JOHNSON & JOHNSON – KEY FACTS
TABLE 37 GLAXOSMITHKLINE PLC – KEY FACTS
TABLE 38 INTAS PHARMACEUTICALS LTD. – KEY FACTS
TABLE 39 PFIZER INC. – KEY FACTS
TABLE 40 GALDERMA S.A. – KEY FACTS
TABLE 41 MERCK & CO., INC. – KEY FACTS
LIST OF FIGURES
FIG 1 RESEARCH SCOPE FOR GLOBAL MUSCLE RELAXANT DRUGS MARKET
FIG 2 RESEARCH METHODOLOGY FOR GLOBAL MUSCLE RELAXANT DRUGS MARKET
FIG 3 APPLICATIONS OF MUSCLE RELAXANTS
FIG 4 CATEGORIES OF SKELETAL MUSCLE RELAXANTS AND THEIR MAJOR DRUGS
FIG 5 TYPES OF NEUROMUSCULAR BLOCKING AGENTS
FIG 6 TYPES OF DEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS, BY TIME OF ACTION
FIG 7 USAGE OF MUSCLE RELAXANTS IN FACIAL AESTHETICS
FIG 8 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION IN MAJOR COUNTRIES
FIG 9 BASIC DRUG DEVELOPMENT PROCEDURE
FIG 10 GLOBAL MUSCLE RELAXANT DRUGS MARKET SIZE, $M (2011 – 2020)
FIG 11 GLOBAL MUSCLE RELAXANT DRUGS MARKET SIZE BY TYPE, $M (2011 – 2020)
FIG 12 GLOBAL MUSCLE RELAXANT DRUGS MARKET SIZE BY GEOGRAPHY, $M (2011 – 2020)
FIG 13 GLOBAL FACIAL AESTHETIC RELAXANTS MARKET SIZE, $M (2011 – 2020)
FIG 14 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANT DRUGS MARKET SHARE, BY REGION (2014 AND 2020)
FIG 15 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET SIZE BY GEOGRAPHY, $M (2011 – 2020)
FIG 16 GLOBAL FACIAL AESTHETIC MUSCLE RELAXANTS MARKET SIZE BY DRUG, $M (2011 – 2020)
FIG 17 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET SIZE, $M (2011 – 2020)
FIG 18 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET SHARE, BY GEOGRAPHY (2014 AND 2020)
FIG 19 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET SIZE BY GEOGRAPHY, $M (2011 – 2020)
FIG 20 GLOBAL SKELETAL MUSCLE RELAXANTS MARKET SIZE BY DRUG, $M (2011 – 2020)
FIG 21 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET SIZE, $M (2011 – 2020)
FIG 22 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET SHARE, BY GEOGRAPHY (2014 AND 2020)
FIG 23 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET SIZE BY GEOGRAPHY, $M (2011 – 2020)
FIG 24 GLOBAL NEUROMUSCULAR BLOCKING AGENTS MARKET SIZE BY TYPE, $M (2011 – 2020)
FIG 25 GLOBAL MUSCLE RELAXANT DRUGS MARKET SIZE, BY COUNTRY
FIG 26 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET SIZE, $M (2011 – 2020)
FIG 27 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)
FIG 28 NORTH AMERICA MUSCLE RELAXANT DRUGS MARKET SHARE, BY COUNTRY (2014)
FIG 29 EUROPE MUSCLE RELAXANT DRUGS MARKET SIZE, $M (2011–2020)
FIG 30 EUROPE MUSCLE RELAXANT DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)
FIG 31 EUROPE MUSCLE RELAXANT DRUGS MARKET SHARE, BY COUNTRY (2014)
FIG 32 ASIA MUSCLE RELAXANT DRUGS MARKET SIZE, $M (2011–2020)
FIG 33 ASIA MUSCLE RELAXANT DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)
FIG 34 ASIA MUSCLE RELAXANT DRUGS MARKET SHARE, BY COUNTRY (2014)
FIG 35 ROW MUSCLE RELAXANT DRUGS MARKET SIZE, $M (2011–2020)
FIG 36 ROW MUSCLE RELAXANT DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)
FIG 37 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS
FIG 38 MARKET SHARE OF KEY PLAYERS IN THE GLOBAL MUSCLE RELAXANT DRUGS MARKET (2014)